Julie Gardener
New Member
Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
Vanessa Deveaux,#1,2 Thomas Cadoudal,#1,2 Yasukatsu Ichigotani,#1,2 Fatima Teixeira-Clerc,1,2 Alexandre Louvet,1,2 Sylvie Manin,1,2 Jeanne Tran-Van Nhieu,1,2,4 Marie Pierre Belot,1,2 Andreas Zimmer,5 Patrick Even,6 Patrice D. Cani,7 Claude Knauf,7 Remy Burcelin,7 Adeline Bertola,8,9,10 Yannick Le Marchand-Brustel,8,9,10 Philippe Gual,8,9,10 Ariane Mallat,1,2,3 and Sophie Lotersztajn1,2,3*
1INSERM, U955, Créteil, France
2Université Paris Est, Faculté de Médecine, Créteil, France
3AP-HP, Groupe Hospitalier Henri Mondor РAlbert Chenevier, Service d'H̩patologie et de Gastroent̩rologie, Cr̩teil, France
4AP-HP, Groupe Hospitalier Henri Mondor РAlbert Chenevier, D̩partement de Pathologie, Cr̩teil, France
5Department of Molecular Psychiatry, University of Bonn, Bonn, Germany
6INRA, UMR914, AgroParisTech, Physiologie de la Nutrition et du Comportement Alimentaire, CNRH-IdF, Paris, France
7INSERM, U858, Toulouse, France
8INSERM, U895, Team 8, Nice, France
9University of Nice-Sophia-Antipolis, Faculty of Medicine, Nice, France
10Centre Hospitalier Universitaire of Nice, Digestive Center, Nice, France
Carlo Polidori, Editor
University of Camerino, Italy
#Contributed equally.
* E-mail: sophie.lotersztajn@inserm.fr
Conceived and designed the experiments: VD TC YI AM SL. Performed the experiments: VD TC YI FTC AL SM MPB PE PDC CK AB. Analyzed the data: VD TC YI JTVN PE RB YLMB PG AM SL. Contributed reagents/materials/analysis tools: VD TC YI SM MPB AZ PE PDC CK RB AB YLMB PG. Wrote the paper: YLMB PG AM SL.
Received April 16, 2009; Accepted May 13, 2009.
This article has been cited by other articles in PMC.
Abstract
Background
Obesity-associated inflammation is of critical importance in the development of insulin resistance and non-alcoholic fatty liver disease. Since the cannabinoid receptor CB2 regulates innate immunity, the aim of the present study was to investigate its role in obesity-induced inflammation, insulin resistance and fatty liver.
Methodology
Murine obesity models included genetically leptin-deficient ob/ob mice and wild type (WT) mice fed a high fat diet (HFD), that were compared to their lean counterparts. Animals were treated with pharmacological modulators of CB2 receptors. Experiments were also performed in mice knock-out for CB2 receptors (Cnr2 −/−).
Principal Findings
In both HFD-fed WT mice and ob/ob mice, Cnr2 expression underwent a marked induction in the stromal vascular fraction of epididymal adipose tissue that correlated with increased fat inflammation. Treatment with the CB2 agonist JWH-133 potentiated adipose tissue inflammation in HFD-fed WT mice. Moreover, cultured fat pads isolated from ob/ob mice displayed increased Tnf and Ccl2 expression upon exposure to JWH-133. In keeping, genetic or pharmacological inactivation of CB2 receptors decreased adipose tissue macrophage infiltration associated with obesity, and reduced inductions of Tnf and Ccl2 expressions. In the liver of obese mice, Cnr2 mRNA was only weakly induced, and CB2 receptors moderately contributed to liver inflammation. HFD-induced insulin resistance increased in response to JWH-133 and reduced in Cnr2 −/− mice. Finally, HFD-induced hepatic steatosis was enhanced in WT mice treated with JWH-133 and blunted in Cnr2 −/− mice.
Conclusion/Significance
These data unravel a previously unrecognized contribution of CB2 receptors to obesity-associated inflammation, insulin resistance and non-alcoholic fatty liver disease, and suggest that CB2 receptor antagonists may open a new therapeutic approach for the management of obesity-associated metabolic disorders.
Introduction
Along with the alarming rise in obesity to epidemic proportions, related complications such as diabetes mellitus, insulin resistance, cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) are also growing and represent some of the leading health-care concerns [1]–[3]. Several studies have conclusively demonstrated that a chronic low-grade systemic inflammatory state, predominantly arising from adipose tissue and liver, plays a critical role in the development of these obesity-related comorbidities [4]–[7]. Thus, in adipose tissue, fat laden adipocytes initiate the inflammatory response by producing cytokines and chemokines, including MCP-1, TNFα and osteopontin, that promote recruitment of proinflammatory macrophages and further amplification of local inflammation [4]–[9]. Increased adipose tissue inflammation will contribute to insulin resistance by disrupting insulin-dependent signaling pathways, leading to increased delivery of free fatty acids to the liver, and thereby contributing to hepatic steatosis [10]. Moreover, fatty liver itself also induces a local subacute inflammatory state characterized by production of inflammatory mediators such as TNFα or IL-6, that directly contribute to hepatic and systemic insulin resistance [3].
Cannabinoid receptors CB1 and CB2 belong to the family of G protein-coupled receptors, and bind exogenous ligands derived from Cannabis Sativa as well as endogenous arachidonic-derived ligands (endocannabinoids) among which anandamide or 2-arachidonoylglycerol are the best characterized [11]–[13]. CB1 receptors play a key role in the pathogenesis of obesity, insulin resistance and NAFLD via central and peripheral effects [11], [14]. CB2 receptors are primarily expressed in cells of the immune system, including macrophages, and regulate the inflammatory response in various settings [15]. Thus, preclinical studies have demonstrated the critical role of CB2 receptors in the inflammatory process associated with rheumatoid arthritis, inflammatory bowel diseases, atherosclerosis or liver ischemia-reperfusion injury [15]–[18]. The aim of the present study was therefore to investigate the role of CB2 receptors in obesity-associated inflammation, insulin resistance and NAFLD.
Methods
Animals and Experimental Design
Mice used for the experiments included wild type (WT) C57Bl/6J, ob/ob and ob+/ob male mice (Janvier, France) and mice with a targeted mutation of the Cnr2 gene [19]. To obtain single mutant mice on an inbred congenic genetic background, heterozygous Cnr2 +/− mice were backcrossed with WT C57Bl/6J (The Jackson Laboratory) animals over 10 generations. Heterozygous mice from the N10 generation were intercrossed to homozygous Cnr2 −/− animals. Genotyping was performed on tail genomic DNA using QuantiTect™ SYBR® Green PCR kit (Qiagen), with the following primers: mouse Cnr2: sense 5′-CTGTGCTGCTCATATGCTGG-3′, antisense 5′-GCAGAGCGAATCTCTCCACT-3′. We also verified that Cnr2 −/− mice still expressed CB1 receptors, using the following primers: mouse Cnr1: sense 5′-CTCCTGGCACCTCTTTCTCAG-3′, antisense 5′-GTCTCCTGCTGGAACCAACGG-3′.
Experimental protocols were conducted in accordance with French government policies (Services véterinaires de la Santé et de la production animale, Ministère français de l′Agriculture). Adult male mice were housed under 12 hours of light/12 hours of dark cycle, in a temperature-controlled environment. WT C57Bl/6J mice and Cnr2 −/− mice (7–10 week-old) were fed a standard chow (TD 2016, Harlan) or a high fat diet (36% fat, TD 99249, Harlan) for 6 or 15 weeks, as indicated. Body weight and food intake were measured weekly.
The impact of the CB2 agonist JWH-133 (Tocris, France) was evaluated in 8-week-old C57Bl/6J mice under ND or HFD for 6 weeks that were treated with JWH-133 during the last 15 days. In some experiments, the effect of the CB2 antagonist AM-630 (Tocris, France) was evaluated in 6-week-old obese male mice (ob/ob) and lean counterparts (ob+/ob). JWH-133 and AM-630 were freshly dissolved in a vehicle solution containing 1 drop of Tween 20 in 0.1 ml dimethylsulfoxide (DMSO), sonicated, and further diluted 50 times in NaCl 9‰. Mice received a 15-day course of daily JWH-133 (3 mg/kg) intraperitoneal injection (n=10 HFD-fed WT mice, and n=6 ND-fed WT mice) or of 1 mg/kg AM-630 (n=10 ob/ob and n=5 ob+/ob). Control animals were treated in parallel with vehicle. Body weight and food intake were measured daily.
In all the experiments, mice were sacrificed after overnight fasting. White epididymal adipose tissue and liver were removed, weighed and either fixed in buffered formalin, or snap frozen in liquid nitrogen. All samples were stored at −80°C until use.
Preparation of adipocyte and stromal vascular fraction (SVF) from adipose tissue
Epididymal adipose tissues from ob+/ob and ob/ob mice were chopped and rinsed in buffer A containing 120 mM NaCl, 4 mM KH2PO4, 1 mM MgSO4, 750 µM CaCl2, 10 mM NaHCO3 and 30 mM HEPES pH 7.4. Explants were incubated at 37°C for 30 minutes in 10 ml of buffer A supplemented with 1% BSA, 280 mM glucose and 15 mg of type 1 collagenase (Clostrido peptidase A, Sigma). Adipocytes were then collected by filtration and floatation, and the SVF was obtained following further centrifugation for 15 min at 260 g and two washings in buffer A. Purity of the fractions was evaluated by Emr1 and Adipoq expressions (not shown). All samples were stored at −80°C until use.
Preparation of hepatocyte and non parenchymal liver cell fraction
Livers from ob+/ob and ob/ob mice were perfused in vivo by Liberase® (Roche) through portal vein. Livers were then dissociated with forceps in Williams medium contanining 10% FCS. Hepatocytes were obtained after filtration and sedimentation while the supernatant was centrifugated at 300 g for 10 min to obtain the non parenchymal cell fraction.
Adipose tissue and liver histology
Fat and liver specimens were fixed in 10% formalin, paraffin-embedded and tissue sections (8 and 4 µm, respectively) were stained with hematoxylin-eosin for routine examination. Adipocyte size was quantified on at least 30 cells from 3 separate fields in 7 WT and 5 Cnr2 −/− HFD-fed animals, using Image J software. Hepatic steatosis was blindly assessed on 4 random fragments from different areas of each liver (n=10 WT and n=10 Cnr2 −/− HFD-fed animals), and was staged on a scale of 0 to 4, according to the percentage of hepatocytes containing cytoplasmic vacuoles as follows: 0, (<5%), 1 (5–20%), 2 (20%–30%), 3 (30–60%), 4 (≥60%).
Indirect calorimetry
In vivo indirect open circuit calorimetry was performed as previously described [20], [21]. Briefly, the mice (HFD-fed WT (n=7) and HFD-fed Cnr2−/− (n=7)) were housed individually in the metabolic cage at 09:30 with water, but without food. Temperature in the metabolic cage was maintained at 32°C±0.5 (low range of thermoneutrality), with an artificial 12 h–12 h light-dark cycle. Respiratory exchanges and spontaneous activity were continuously recorded at 10 s interval from 10:00 until 09:00 the following day. Resting and activity-related metabolic rates were calculated a posteriori using the Kalman filtering method [21]. Basal metabolic rate and basal RQ were defined as the mean resting metabolic rate measured between 16:00 and 18:00 when the mice were in a post-absorptive state, just before the 1g-test meal was given. Post meal RQ was defined as the mean RQ measured during 6 hrs following administration of the 1g-test meal (until metabolic rate returned to pre-meal values); peak post meal is defined as the highest value of RQ recorded during the post meal period. Energy expended with activity was calculated from the difference between total and resting metabolism.
Fecal fat excretion
The amount of fat in dried feces (n=7 cages of 5 mice in each group) was measured by the Laboratory of Functional Coprology, Pitié-Salpétrière Hospital, Paris France.
Culture of explants from adipose tissue
Explants of epididymal adipose tissue were prepared from ob/ob male mice, following overnight fasting. Epididymal adipose tissue samples were cut into small pieces (1 mm3) under sterile conditions and rinsed in Dulbecco's modified Eagle medium (DMEM, Invitrogen). Explants (200 mg) were further incubated for 48 hours at 37°C in DMEM supplemented with 12.5 mM glucose, 200 IU/ml penicillin, 50 mg/l streptomycin, and 2% BSA, and further exposed to 1 µM JWH-133 (Tocris, France) or vehicle (DMSO 0.02%). After 48 hours, samples were frozen in liquid nitrogen and stored at −80°C before RNA extraction.
Serum analysis
Blood was collected at the time of sacrifice, fasting glycemia were determined by Accu-Check active bands (Roche Diagnostics) and insulinemia by Elisa (Ultrasensitive mouse sensitive Elisa, Mercodia), respectively.
Hepatic triglyceride quantification
Hepatic triglycerides were extracted from 50 mg of liver homogenates by homogenization in 1 ml of chloroform-methanol (21 v/v) using TissueLyser (Qiagen). The homogenate was centrifuged for 10 min at 1000 g, and the lipid phase was diluted with 0.2 ml water. Following an additional centrifugation for 20 min at 2400 rpm, the lipid extract was collected from the lower phase, evaporated and dissolved in 1 ml of 2-propanol. Triglycerides were quantified with a triglyceride determination kit (Sigma), on liver samples from 10–15 animals per group.
Insulin tolerance test
Mice (7–10 per group) underwent a 0.75 U/kg i.p. injection of human insulin (Insulin NPH; Lilly), following a 3 h fasting. Blood samples were taken from the tail vein for determination of glycemia at time 0 and 20, 30, 40, 60, 90, 120, and 180 min after the insulin injection.
Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic- euglycemic clamp was performed as previously described [22]. Briefly, 6h-fasted WT (n=6) and Cnr2 −/− (n=7) mice fed a HFD for 15 weeks, received simultaneous infusions of insulin (18 mU.kg−1.min−1 for 3 h), and D-(3H)3-glucose (30 µCi.kg−1.min−1), Perkin Elmer, Boston, MA) to ensure a detectable D-(3H)3-glucose enrichment. Glycemia was assessed throughout the infusion from blood samples collected from the tip of the tail vein and euglycemia was maintained by adjusting a variable infusion of 30% (wt/vol) glucose. Plasma glucose concentrations and D-(3H)3-glucose specific activity were determined in 5 µl of blood sampled from the tip of the tail vein every 10 min during the last hour of the infusion. The enrichment in D-(3H)3-glucose was determined from total blood after deproteinization by a Zn(OH)2 precipitation as previously described [22]. An aliquot of the protein-free supernatant was evaporated to dryness and mixed with scintillation fluid to determine the radioactivity corresponding to D-[3H]3-glucose. In a second aliquot of the same supernatant, glucose concentration was measured by the glucose oxidase method (Sigma).
RNA preparation and RT-PCR
Total RNA was extracted from mice epididymal fat, liver and brain using RNeasy® Lipid Tissue Mini kit (Qiagen). Quantitative RT-PCR was carried out on a Light Cycler (Roche Diagnostics), as previously described [23]. Oligonucleotide primer sequences of the mouse genes studied were the following. mouse Rn18S: sense 5′-ACCAGAGCGAAAGCATTTGCCA-3′, antisense: 5′-ATCGCCAGTCGGCATCGTTTAT-3′; mouse Cnr2: sense 5′-GGATACAGAATAGCCAGGAC-3′, antisense 5′-GGAGCCGTTGGTCACTTCTG-3′; mouse Cnr1: sense 5′-GGGCAAATTTCCTTGTAGCA-3′, antisense 5′-CTGCAAGGCCGTCTAAGATCGACT-3′; mouse Ccl2: sense 5′-GGGCCTGCTGTTCACAGTT-3′, antisense 5′-CCAGCCTACTCATTGGGAT-3′; mouse Emr1: sense 5′-CTTTGGCTATGGGCTTCCAGTC-3′, antisense 5′-GCAAGGAGGACAGAGTTTATCGTG-3′; mouse Tnf: sense 5′-AATGGCCTCCCTCTCATCAGTT-3′, antisense 5′-CCACTTGGTGGTTTGCTACGA-3′. PCR amplified products were analyzed on a 2% agarose gel and sequenced.
Immunohistochemistry
Immunohistochemical detection of F4/80 was performed in epididymal adipose formalin-fixed, parraffin-embedded tissue sections (8 µm), using non-diluted antibody to F4/80 (Serotec MCA 497) and biotinylated secondary antibody (1/50, Serotec AAR10B). The signal was amplified with phosphatase alkaline–conjugated streptavidin (1/20, Serotec), and alkaline phosphatase activity was revealed using fast red substrate–chromogen system (Dakocytomation). The total number of F4/80 expressing cells was quantified on at least 500 cells from 5 random fields in 7 vehicle-treated or 7 AM-630-treated WT mice fed a HFD, and 5 Cnr2 −/− HFD-fed animals, using Image J software. Results are expressed as F4/80 stained cells/total cells.
Statistics
Results are expressed as mean±SEM and were analyzed by either Mann and Whitney test, one or two way ANOVA as appropriate, using PRISM 4.0 software. P<0.05 was taken as the minimum level of significance.
Results
Characterization of CB2 receptor expression in the adipose tissue and the liver during obesity
We first characterized the expression of Cnr2 (encoding CB2) in the adipose tissue and in the liver, and its regulation overtime during obesity, using genetically obese leptin-deficient ob/ob mice and wild type (WT) C57Bl/6J mice fed a high fat diet (HFD) for 6 or 15 weeks. In the two models, Cnr2 expression was detected in the epididymal adipose tissue of lean animals, and its expression was enhanced in obese mice in parallel to body weight increase (Fig 1A). Moreover, in both models, the induction of fat Cnr2 expression was correlated with adipose tissue inflammation, as shown by the concurrent increase in the expression of Emr1, encoding the macrophage related marker F4/80 (Fig 1A). In keeping, epididymal adipose tissue fractionation experiments showed that Cnr2 was predominantly expressed in the stromal vascular fraction, both in lean ob+/ob and obese ob/ob animals, and was barely detectable in the adipocyte fraction (Fig 1B). Obesity was associated with a modest 1.8-fold increase in Cnr2 expression in the liver, both in ob/ob and HFD-fed animals (Fig 1C). In keeping with findings in the adipose tissue, Cnr2 was primarily expressed by the non parenchymal liver cell fraction in lean ob+/ob and in obese ob/ob animals, whereas Cnr2 was hardly detectable in the hepatocyte fraction (Fig 1D). Overall, these results indicate that obesity enhances Cnr2 expression in the non parenchymal cell fraction of adipose tissue and liver.
Figure 1
Selective distribution of Cnr2 in the adipose tissue and regulation during obesity.
CB2 receptors promote obesity-associated inflammation
Given the regulatory role of Cnr2 in inflammation [15], we next explored the possibility that CB2 receptors may regulate fat and liver inflammation. To that aim, C57Bl/6J mice were fed a HFD or a normal diet (ND) and sacrificed after 6 weeks, i.e at the early onset of inflammation in obese mice. In addition, both groups of mice received a daily intraperitoneal injection of the selective CB2 receptor agonist JWH-133 (3 mg/kg) or its vehicle during the last 2 weeks [24], [25]. Administration of JWH-133 did not affect body weight progression of either HFD or ND-fed mice (Fig 2A). As expected, vehicle-treated HFD-fed mice showed a moderate induction of epididymal fat Emr1 and Tnf expressions, whereas the expression of Ccl2, encoding MCP-1, was already strongly increased (Fig 2B). Interestingly, administration of JWH-133 to ND-fed WT mice induced Emr1 and Tnf expression, as compared to vehicle-treated ND counterparts (Fig 2B). Moreover, the compound further potentiated inductions of fat Emr1 and Tnf in HFD-fed animals (Fig 2B). However, JWH-133 treatment had no effect on Ccl2 expression either in ND or in HFD-fed mice (Fig 2B). The impact of JWH-133 was also investigated in cultured fat pads isolated from ob/ob mice. Cultured fat pads exposed to JWH-133 showed a marked induction in both Tnf and Ccl2 expressions (Fig 2C). Finally, in the liver of mice fed a ND or a HFD, JWH-133 had little or no effect on Ccl2 and Tnf expression respectively (Fig 2D). Taken together, these data demonstrate that the role of CB2 receptor is critical in adipose tissue inflammation, but less determinant in liver inflammation.
Figure 2
Activation of CB2 receptors by JWH-133 enhances fat inflammation in HFD-fed mice.
We next investigated whether CB2 receptor antagonism reduced obesity-associated inflammation. A 2-week treatment of ob/ob mice with the CB2 receptor antagonist AM-630 (1 mg/kg/day) did not affect body weight progression [26] (Fig 3A) while reducing adipose tissue inflammation, as reflected by the reduction in the accumulation of F4/80 positive cells and of Emr1, Tnf and Ccl2 expression (Fig 3B and C). Moreover, in control lean ob+/ob mice there was a trend towards reduced fat inflammation in AM-630 treated animals compared to lean vehicle-exposed controls (Fig 3B and C). These results were confirmed in Cnr2−/− mice fed a HFD for 15 weeks. Compared to HFD-fed WT mice, HFD-fed Cnr2−/− animals exhibited a significant reduction in fat macrophage density (Fig 4A) and a lesser induction of Emr1, Tnf and Ccl2 (Fig 4B). Finally, livers of HFD-fed Cnr2−/− mice also showed a decline in inflammation, as compared to their WT counterparts (Fig 4C). Overall, these data demonstrate that CB2 receptor inactivation reduces inflammation both in adipose tissue and in the liver of obese animals.
Figure 3
Pharmacological inactivation of CB2 receptors reduces the inflammatory response in the adipose tissue.
Figure 4
Cnr2 knock-out reduces the inflammatory response in the adipose tissue and the liver.
Deletion of Cnr2 reduces body weight progression under HFD
Surprisingly, Cnr2 knock-out was also associated with a slower body weight progression that becomes significant after 8 weeks of HFD (p<0.05 by two way ANOVA) (Fig 4D). Accordingly, Cnr2 −/− mice also displayed smaller adiposity index and adipocyte size compared to WT animals (Table 1), and reduced circulating leptin levels, whereas serum adiponectin levels were unchanged (Table 1). Subsequent experiments investigated mechanisms underlying Cnr2 impact on obesity.
Table 1
Metabolic parameters of HFD WT and Cnr2 −/− mice.
Since the cannabinoid receptor CB1 plays a key role in the pathogenesis of obesity by increasing food intake and reducing energy expenditure, we first characterized Cnr1 expression in brain, adipose tissue and liver. There was no difference in brain Cnr1 expression between HFD-fed WT and Cnr2−/− mice. However, surprisingly, Cnr1 expression was decreased in the adipose tissue and the liver of HFD-fed Cnr2 −/− mice as compared to their WT counterparts (Table 1). In contrast, livers and adipose tissue isolated from JWH-133 or AM-630 treated animals showed no difference in Cnr1 levels (not shown). These data suggested that the reduction of Cnr1 expression in the adipose tissue and liver observed in Cnr2 −/− mice might account for the reduction in body weight progression in these animals, a reduction that is not observed in WT mice treated with pharmacological agonists or antagonists of CB2 receptors. The next series of experiments were therefore designed to further delineate the mechanisms underlying the Cnr2−/− mice phenotype.
Several studies have reported that Cnr1 knock-out decreases food intake and increases energy expenditure. However, food intake was similar in Cnr2−/− and WT mice fed a HFD (Table 1). Indirect calorimetry showed that HFD-fed Cnr2 −/− and WT mice had similar basal and total metabolic rate, exhibited the same level of spontaneous activity (Table 1), and equivalent thermogenic response to feeding (not shown). Nevertheless, Cnr2−/− mice tended to display a lower pre-meal, post meal and overall respiratory quotient, although the differences with WT animals did not reach statistical significance (data not shown). In addition, the peak of meal-induced RQ increase was significantly reduced in Cnr2 −/− animals, compared to WT (Table 1), therefore indicating that Cnr2 knock-out may reduce the inhibition of lipid oxidation induced by feeding. Finally, quantification of fat elimination in faeces showed a modest albeit significant increase in fecal lipid output in HFD-fed Cnr2 −/− mice, as compared to WT counterparts (Table 1), by a mechanism that may involve inhibition of pancreatic lipase gene expression (Cadoudal et al, preliminary results). Overall, these data indicate Cnr2 knock-out attenuates the progression of obesity by a mechanism distinct from that elicited by CB1 antagonism, possibly by increasing both lipid oxidation and fecal fat excretion.
CB2 receptors promote insulin resistance
We next examined the impact of CB2 receptors on obesity-associated insulin resistance, a reported consequence of inflammation. As expected, WT mice fed a HFD for 15 weeks developed hyperglycemia and hyperinsulinemia, resulting in increased HOMA-IR (Fig 5A). In contrast, the increase in insulin plasma levels and HOMA-IR was significantly lower in HFD-fed Cnr2 −/− mice (Fig 5A). Consistent with these results, insulin tolerance test showed that HFD-fed Cnr2 −/− mice were more insulin sensitive than their WT counterparts (p<0.05 by two way ANOVA) (Fig 5B). These findings were further corroborated in hyperinsulinemic-euglycemic clamp experiments (Fig 5C). Indeed, glucose turnover and glycolysis rate were increased in HFD-fed Cnr2 −/− mice, whereas glycogen synthesis rate remained unchanged, confirming the insulin sensitizing effects of Cnr2 knock-out (Fig 5C). Accordingly, in mice exposed to a HFD for 6 weeks, treatment with the CB2 agonist JWH-133 enhanced insulin resistance, as assessed by the insulin tolerance test (p<0.05 by two way ANOVA) (Fig 5 D). Collectively, these results demonstrate that CB2 receptors enhance obesity-associated insulin resistance.
Figure 5
CB2 receptors potentiate insulin resistance in HFD-fed mice.
CB2 receptors promote fatty liver
Obesity-associated fatty liver has been causally linked to adipose tissue inflammation and insulin resistance. As expected, WT mice fed a HFD for 15 weeks developed severe fatty liver (Fig 6A). In contrast, HFD-fed Cnr2 −/− animals exhibited minimal steatosis, as illustrated by the decrease in the steatosis score (Fig 6A) and the decline in liver triglyceride concentration, compared to HFD-fed WT animals (Fig 6B). In keeping with these results, administration of JWH-133 enhanced liver triglyceride accumulation in WT mice fed a HFD for 6 weeks (Fig 6B). Taken together, these findings indicate that CB2 receptors potentiate obesity-associated fatty liver.
Figure 6
CB2 receptors promote the development of hepatic steatosis.
Discussion
Our study unravels a previously unrecognized contribution of CB2 receptors to the pathogenesis of obesity associated-comorbodities via an impact on obesity-associated inflammation, insulin resistance and fatty liver.
Recent studies have conclusively shown that adipose tissue and liver inflammation plays a major role in obesity-associated insulin resistance and NAFLD [4]–[7], [27], [28]. Our data indicate that during obesity progression, Cnr2 expression undergoes a strong increase in adipose tissue parallel to the development of fat inflammation, and a moderate induction in the liver. Tissue fractionation experiments show that enhancement of Cnr2 expression arises from the macrophage-enriched stromal vascular fraction of the adipose tissue and the non parenchymal liver cell fraction, whereas Cnr2 expression in adipocytes and hepatocytes remains negligible. Pharmacological activation of CB2 receptors has no significant impact on liver inflammation but promotes a significant enhancement of adipose tissue inflammation at an early stage. Indeed, administration of JWH-133 at the onset of inflammation, i.e. in mice fed a HFD for 6 weeks, increases fat macrophage infiltration and the related inflammatory response. Moreover, pharmacological and genetic CB2 receptor inactivation reduce adipose tissue and liver inflammation in the long term, as shown in ob/ob mice or animals fed a HFD for 15 weeks. Interestingly, in isolated fat pads, the CB2 receptor agonist JWH-133 upregulates Ccl2 and Tnf, demonstrating the direct impact of CB2 receptors to adipose tissue inflammation. Nevertheless, in light of previous data showing Cnr2 expression in human adipocytes and in adipocyte cell lines [29], [30], the contribution of adipocyte CB2 receptors to fat inflammation cannot be definitively ruled out. Mechanisms underlying the impact of CB2 receptors on macrophage recruitment remain to be determined. Potential pathways could involve enhanced chemotaxis and/or increased macrophage migration, considering reported stimulatory effects of CB2 receptors on these two functions in other conditions [15], [31]–[33]. The relative contribution of liver vs adipose tissue inflammation remains to be determined. Nevertheless, our data unravel the critical role of CB2 receptors in obesity-associated inflammation.
Insulin resistance associated with obesity has been linked to adipose tissue inflammation [4]–[7]. In keeping with these studies, our data suggest that proinflammatory properties of adipose tissue CB2 receptors may contribute to the development of insulin resistance. Indeed, under HFD, JWH-133-treated WT mice show enhanced insulin resistance and fat inflammation, whereas Cnr2 −/− mice display improved insulin sensitivity and reduced fat inflammation. It should also be stressed that, aside from their impact on fat inflammation, CB2 receptors expressed by other insulin sensitive tissues, including skeletal muscle and liver [23], [34], [35] may also contribute to insulin resistance. In addition, deleterious effects of CB2 receptors on insulin secretion may also be expected, in light of the inhibition of insulin secretion triggered by CB2 receptors expressed in pancreatic β cells [35], [36].
Our results indicate that fatty liver, a hallmark of obesity-associated metabolic syndrome, is enhanced by the CB2 receptor agonist JWH-133 and blunted by Cnr2 knock-out. Recent data have conclusively shown a causal relationship between obesity-induced overproduction of fat inflammatory mediators such as Ccl2, insulin resistance and steatogenesis. Indeed, insulin resistance enhances the release of non-esterified fatty acids from adipose tissue, leading to increased fatty acid storage in hepatocytes [10]. Moreover, mice overexpressing Ccl2 specifically in adipose tissue exhibit insulin resistance and increased hepatic triglyceride content. Conversely, knock-out of Ccl2 or its receptor Ccr2, improves insulin sensitivity and prevents steatosis [27], [28], [37]. Therefore, it is tempting to speculate that CB2 receptors may enhance fatty liver at least partly by increasing adipose tissue inflammation and the related induction of Ccl2. Other steatogenic mechanisms may include enhancement of lipogenesis and/or inhibition of fatty acid β-oxidation in hepatocytes, following direct activation of Cnr2. However, although expressed in the liver [23], CB2 receptors are undetectable in steatotic hepatocytes.
Recent studies in obese patients have reported elevated circulating levels of the endogenous CB2 ligand 2-arachidonoylglycerol [38] and increased production of the compound by fat cells [39]. These observations, together with our findings demonstrating induction of CB2 receptor in adipose tissue and liver, indicate that alike CB1 tone, the endogenous CB2 tone is increased during obesity [40], [41]. Clinical and experimental studies in obesity have also linked overactivation of CB1 receptors to body weight progression, insulin resistance and fatty liver [11], [14], [42]–[45]. Interestingly, although both receptors display convergent effects, pathways underlying CB1 effects are markedly different from those affected by CB2. Indeed, CB1 receptors mainly enhance food intake, reduce peripheral energy expenditure and enhance hepatic lipogenesis via CB1 receptors expressed by hepatocytes. In contrast, pharmacological modulation of CB2 receptors has no impact on either food intake or body weight progression and predominantly affects adipose tissue inflammation. It should however be pointed out that Cnr2 knock-out was associated with a slight reduction of body weight progression under HFD, that was not observed in WT animals exposed to CB2 agonists or antagonists. This discrepancy may result from developmental defects linked to lifelong absence of CB2 receptors or may be due to the short duration of treatment with the CB2 targeting molecules in our experiments. Nevertheless, our findings indicate that distinct CB1 and CB2 receptor-dependent pathways significantly contribute to the pathogenesis of insulin resistance and NAFLD.
In conclusion, the present study uncovers the potent proinflammatory properties of CB2 receptors during experimental obesity and shows the deleterious impact of CB2 receptors on insulin resistance and fatty liver. These findings further document the crucial role of the endocannabinoid system in metabolic comorbidities associated to obesity, and unravel the previously unrecognized role of CB2 receptors. They also demonstrate that both CB1 and CB2 receptors display convergent effects, via complementary pathways [11], [13], [14]. Finally, our results add novel evidences underscoring the role of CB2 receptors in the pathogenesis of inflammatory disorders [15] and liver diseases [12], [17], [23], [45]–[48]. Lastly, our results suggest that CB2 receptor antagonism may open a novel therapeutic approach for the management of insulin resistance and fatty liver.
Acknowledgments
We thank F. Pecker for helpful and constant guidance, C. Pavoine for helpful comments and S. Balustre for animal handling.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the INSERM, the Universite Paris-Val-de-Marne, and by grants (to SL) of the Agence Nationale de la Recherche and the Fondation pour la Recherche Medicale. V Deveaux was supported by a fellowship from the Association Francaise pour l′Etude du Foie, Y Ichigotani by a fellowship from the Agence Nationale de la Recherche and T Cadoudal by a fellowship from the Fondation pour la Recherche Medicale. A Bertola was successively supported by the Programme Hospitalier de Recherche Clinique (CHU of Nice) and the Association pour la Recherche sur le Cancer. Y Le-Marchand Brustel and P Gual are the recipients of an interface grant from CHU of Nice, and S Lotersztajn of an interface grant from AP-HP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887. [PubMed]
2. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209. [PubMed]
3. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191–2207. [PubMed]
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808. [PMC free article] [PubMed]
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. [PubMed]
6. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180. [PubMed]
7. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830. [PMC free article] [PubMed]
8. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117:2877–2888. [PMC free article] [PubMed]
9. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes. 2009;58:125–133. [PMC free article] [PubMed]
10. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829–838. [PMC free article] [PubMed]
11. Di Marzo V. Targeting the endocannabinoid system:to enhance or reduce? Nature Reviews Drug Discovery. 2008;7:438–455.
12. Mallat A, Lotersztajn S. Endocannabinoids and Their Receptors in the Liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9–G12. [PubMed]
13. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462. [PMC free article] [PubMed]
14. Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1101–1104. [PubMed]
15. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–411. [PubMed]
16. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature Medicine. 2005;434:782–786.
17. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, et al. CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol. 2008;153:286–289. [PMC free article] [PubMed]
18. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. Faseb J. 2007;21:1788–1800. [PMC free article] [PubMed]
19. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141–149. [PubMed]
20. Even PC, Perrier E, Aucouturier JL, Nicolaidis S. Utilisation of the method of Kalman filtering for performing the on-line computation of background metabolism in the free-moving, free-feeding rat. Physiol Behav. 1991;49:177–187. [PubMed]
21. Even PC, Mokhtarian A, Pele A. Practical aspects of indirect calorimetry in laboratory animals. Neurosci Biobehav Rev. 1994;18:435–447. [PubMed]
22. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005;115:3554–3563. [PMC free article] [PubMed]
23. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–755. [PubMed]
24. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, et al. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem. 1999;7:2905–2914. [PubMed]
25. Defer N, Wan J, Souktani R, Escoubet B, Perier M, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. Faseb J 2009
26. Pertwee R, Griffin G, Fernando S, Li X, Hill A, et al. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 1995;56:1949–1955. [PubMed]
27. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602–26614. [PubMed]
28. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–1505. [PMC free article] [PubMed]
29. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 2006;126:177–187. [PubMed]
30. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171–3180. [PubMed]
31. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol. 2008;153:299–308. [PMC free article] [PubMed]
32. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol. 2008;294:H1145–1155. [PubMed]
33. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, et al. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem. 2000;275:15621–15628. [PubMed]
34. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol. 2007;267:63–69. [PubMed]
35. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553–565. [PubMed]
36. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006;39:155–162. [PubMed]
37. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115–124. [PMC free article] [PubMed]
38. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843. [PMC free article] [PubMed]
39. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007;15:837–845. [PubMed]
40. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–3060. [PMC free article] [PubMed]
41. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692–699. [PubMed]
42. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007;46:122–129. [PubMed]
43. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. Paracrine Activation of Hepatic CB(1) Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver. Cell Metab. 2008;7:227–235. [PubMed]
44. Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 2006;6:586–591. [PubMed]
45. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology. 2005;42:63–71.
46. Teixeira-Clerc F, Julien B, Grenard P, Tran-Van-Nhieu J, Deveaux V, et al. CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676.
47. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, et al. Daily cannabis use, a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432–439.
48. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. Journal of Endocrinological Investigation. 2006;29:58–65. [PubMed]
Source: Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
Vanessa Deveaux,#1,2 Thomas Cadoudal,#1,2 Yasukatsu Ichigotani,#1,2 Fatima Teixeira-Clerc,1,2 Alexandre Louvet,1,2 Sylvie Manin,1,2 Jeanne Tran-Van Nhieu,1,2,4 Marie Pierre Belot,1,2 Andreas Zimmer,5 Patrick Even,6 Patrice D. Cani,7 Claude Knauf,7 Remy Burcelin,7 Adeline Bertola,8,9,10 Yannick Le Marchand-Brustel,8,9,10 Philippe Gual,8,9,10 Ariane Mallat,1,2,3 and Sophie Lotersztajn1,2,3*
1INSERM, U955, Créteil, France
2Université Paris Est, Faculté de Médecine, Créteil, France
3AP-HP, Groupe Hospitalier Henri Mondor РAlbert Chenevier, Service d'H̩patologie et de Gastroent̩rologie, Cr̩teil, France
4AP-HP, Groupe Hospitalier Henri Mondor РAlbert Chenevier, D̩partement de Pathologie, Cr̩teil, France
5Department of Molecular Psychiatry, University of Bonn, Bonn, Germany
6INRA, UMR914, AgroParisTech, Physiologie de la Nutrition et du Comportement Alimentaire, CNRH-IdF, Paris, France
7INSERM, U858, Toulouse, France
8INSERM, U895, Team 8, Nice, France
9University of Nice-Sophia-Antipolis, Faculty of Medicine, Nice, France
10Centre Hospitalier Universitaire of Nice, Digestive Center, Nice, France
Carlo Polidori, Editor
University of Camerino, Italy
#Contributed equally.
* E-mail: sophie.lotersztajn@inserm.fr
Conceived and designed the experiments: VD TC YI AM SL. Performed the experiments: VD TC YI FTC AL SM MPB PE PDC CK AB. Analyzed the data: VD TC YI JTVN PE RB YLMB PG AM SL. Contributed reagents/materials/analysis tools: VD TC YI SM MPB AZ PE PDC CK RB AB YLMB PG. Wrote the paper: YLMB PG AM SL.
Received April 16, 2009; Accepted May 13, 2009.
This article has been cited by other articles in PMC.
Abstract
Background
Obesity-associated inflammation is of critical importance in the development of insulin resistance and non-alcoholic fatty liver disease. Since the cannabinoid receptor CB2 regulates innate immunity, the aim of the present study was to investigate its role in obesity-induced inflammation, insulin resistance and fatty liver.
Methodology
Murine obesity models included genetically leptin-deficient ob/ob mice and wild type (WT) mice fed a high fat diet (HFD), that were compared to their lean counterparts. Animals were treated with pharmacological modulators of CB2 receptors. Experiments were also performed in mice knock-out for CB2 receptors (Cnr2 −/−).
Principal Findings
In both HFD-fed WT mice and ob/ob mice, Cnr2 expression underwent a marked induction in the stromal vascular fraction of epididymal adipose tissue that correlated with increased fat inflammation. Treatment with the CB2 agonist JWH-133 potentiated adipose tissue inflammation in HFD-fed WT mice. Moreover, cultured fat pads isolated from ob/ob mice displayed increased Tnf and Ccl2 expression upon exposure to JWH-133. In keeping, genetic or pharmacological inactivation of CB2 receptors decreased adipose tissue macrophage infiltration associated with obesity, and reduced inductions of Tnf and Ccl2 expressions. In the liver of obese mice, Cnr2 mRNA was only weakly induced, and CB2 receptors moderately contributed to liver inflammation. HFD-induced insulin resistance increased in response to JWH-133 and reduced in Cnr2 −/− mice. Finally, HFD-induced hepatic steatosis was enhanced in WT mice treated with JWH-133 and blunted in Cnr2 −/− mice.
Conclusion/Significance
These data unravel a previously unrecognized contribution of CB2 receptors to obesity-associated inflammation, insulin resistance and non-alcoholic fatty liver disease, and suggest that CB2 receptor antagonists may open a new therapeutic approach for the management of obesity-associated metabolic disorders.
Introduction
Along with the alarming rise in obesity to epidemic proportions, related complications such as diabetes mellitus, insulin resistance, cardiovascular disease and non-alcoholic fatty liver disease (NAFLD) are also growing and represent some of the leading health-care concerns [1]–[3]. Several studies have conclusively demonstrated that a chronic low-grade systemic inflammatory state, predominantly arising from adipose tissue and liver, plays a critical role in the development of these obesity-related comorbidities [4]–[7]. Thus, in adipose tissue, fat laden adipocytes initiate the inflammatory response by producing cytokines and chemokines, including MCP-1, TNFα and osteopontin, that promote recruitment of proinflammatory macrophages and further amplification of local inflammation [4]–[9]. Increased adipose tissue inflammation will contribute to insulin resistance by disrupting insulin-dependent signaling pathways, leading to increased delivery of free fatty acids to the liver, and thereby contributing to hepatic steatosis [10]. Moreover, fatty liver itself also induces a local subacute inflammatory state characterized by production of inflammatory mediators such as TNFα or IL-6, that directly contribute to hepatic and systemic insulin resistance [3].
Cannabinoid receptors CB1 and CB2 belong to the family of G protein-coupled receptors, and bind exogenous ligands derived from Cannabis Sativa as well as endogenous arachidonic-derived ligands (endocannabinoids) among which anandamide or 2-arachidonoylglycerol are the best characterized [11]–[13]. CB1 receptors play a key role in the pathogenesis of obesity, insulin resistance and NAFLD via central and peripheral effects [11], [14]. CB2 receptors are primarily expressed in cells of the immune system, including macrophages, and regulate the inflammatory response in various settings [15]. Thus, preclinical studies have demonstrated the critical role of CB2 receptors in the inflammatory process associated with rheumatoid arthritis, inflammatory bowel diseases, atherosclerosis or liver ischemia-reperfusion injury [15]–[18]. The aim of the present study was therefore to investigate the role of CB2 receptors in obesity-associated inflammation, insulin resistance and NAFLD.
Methods
Animals and Experimental Design
Mice used for the experiments included wild type (WT) C57Bl/6J, ob/ob and ob+/ob male mice (Janvier, France) and mice with a targeted mutation of the Cnr2 gene [19]. To obtain single mutant mice on an inbred congenic genetic background, heterozygous Cnr2 +/− mice were backcrossed with WT C57Bl/6J (The Jackson Laboratory) animals over 10 generations. Heterozygous mice from the N10 generation were intercrossed to homozygous Cnr2 −/− animals. Genotyping was performed on tail genomic DNA using QuantiTect™ SYBR® Green PCR kit (Qiagen), with the following primers: mouse Cnr2: sense 5′-CTGTGCTGCTCATATGCTGG-3′, antisense 5′-GCAGAGCGAATCTCTCCACT-3′. We also verified that Cnr2 −/− mice still expressed CB1 receptors, using the following primers: mouse Cnr1: sense 5′-CTCCTGGCACCTCTTTCTCAG-3′, antisense 5′-GTCTCCTGCTGGAACCAACGG-3′.
Experimental protocols were conducted in accordance with French government policies (Services véterinaires de la Santé et de la production animale, Ministère français de l′Agriculture). Adult male mice were housed under 12 hours of light/12 hours of dark cycle, in a temperature-controlled environment. WT C57Bl/6J mice and Cnr2 −/− mice (7–10 week-old) were fed a standard chow (TD 2016, Harlan) or a high fat diet (36% fat, TD 99249, Harlan) for 6 or 15 weeks, as indicated. Body weight and food intake were measured weekly.
The impact of the CB2 agonist JWH-133 (Tocris, France) was evaluated in 8-week-old C57Bl/6J mice under ND or HFD for 6 weeks that were treated with JWH-133 during the last 15 days. In some experiments, the effect of the CB2 antagonist AM-630 (Tocris, France) was evaluated in 6-week-old obese male mice (ob/ob) and lean counterparts (ob+/ob). JWH-133 and AM-630 were freshly dissolved in a vehicle solution containing 1 drop of Tween 20 in 0.1 ml dimethylsulfoxide (DMSO), sonicated, and further diluted 50 times in NaCl 9‰. Mice received a 15-day course of daily JWH-133 (3 mg/kg) intraperitoneal injection (n=10 HFD-fed WT mice, and n=6 ND-fed WT mice) or of 1 mg/kg AM-630 (n=10 ob/ob and n=5 ob+/ob). Control animals were treated in parallel with vehicle. Body weight and food intake were measured daily.
In all the experiments, mice were sacrificed after overnight fasting. White epididymal adipose tissue and liver were removed, weighed and either fixed in buffered formalin, or snap frozen in liquid nitrogen. All samples were stored at −80°C until use.
Preparation of adipocyte and stromal vascular fraction (SVF) from adipose tissue
Epididymal adipose tissues from ob+/ob and ob/ob mice were chopped and rinsed in buffer A containing 120 mM NaCl, 4 mM KH2PO4, 1 mM MgSO4, 750 µM CaCl2, 10 mM NaHCO3 and 30 mM HEPES pH 7.4. Explants were incubated at 37°C for 30 minutes in 10 ml of buffer A supplemented with 1% BSA, 280 mM glucose and 15 mg of type 1 collagenase (Clostrido peptidase A, Sigma). Adipocytes were then collected by filtration and floatation, and the SVF was obtained following further centrifugation for 15 min at 260 g and two washings in buffer A. Purity of the fractions was evaluated by Emr1 and Adipoq expressions (not shown). All samples were stored at −80°C until use.
Preparation of hepatocyte and non parenchymal liver cell fraction
Livers from ob+/ob and ob/ob mice were perfused in vivo by Liberase® (Roche) through portal vein. Livers were then dissociated with forceps in Williams medium contanining 10% FCS. Hepatocytes were obtained after filtration and sedimentation while the supernatant was centrifugated at 300 g for 10 min to obtain the non parenchymal cell fraction.
Adipose tissue and liver histology
Fat and liver specimens were fixed in 10% formalin, paraffin-embedded and tissue sections (8 and 4 µm, respectively) were stained with hematoxylin-eosin for routine examination. Adipocyte size was quantified on at least 30 cells from 3 separate fields in 7 WT and 5 Cnr2 −/− HFD-fed animals, using Image J software. Hepatic steatosis was blindly assessed on 4 random fragments from different areas of each liver (n=10 WT and n=10 Cnr2 −/− HFD-fed animals), and was staged on a scale of 0 to 4, according to the percentage of hepatocytes containing cytoplasmic vacuoles as follows: 0, (<5%), 1 (5–20%), 2 (20%–30%), 3 (30–60%), 4 (≥60%).
Indirect calorimetry
In vivo indirect open circuit calorimetry was performed as previously described [20], [21]. Briefly, the mice (HFD-fed WT (n=7) and HFD-fed Cnr2−/− (n=7)) were housed individually in the metabolic cage at 09:30 with water, but without food. Temperature in the metabolic cage was maintained at 32°C±0.5 (low range of thermoneutrality), with an artificial 12 h–12 h light-dark cycle. Respiratory exchanges and spontaneous activity were continuously recorded at 10 s interval from 10:00 until 09:00 the following day. Resting and activity-related metabolic rates were calculated a posteriori using the Kalman filtering method [21]. Basal metabolic rate and basal RQ were defined as the mean resting metabolic rate measured between 16:00 and 18:00 when the mice were in a post-absorptive state, just before the 1g-test meal was given. Post meal RQ was defined as the mean RQ measured during 6 hrs following administration of the 1g-test meal (until metabolic rate returned to pre-meal values); peak post meal is defined as the highest value of RQ recorded during the post meal period. Energy expended with activity was calculated from the difference between total and resting metabolism.
Fecal fat excretion
The amount of fat in dried feces (n=7 cages of 5 mice in each group) was measured by the Laboratory of Functional Coprology, Pitié-Salpétrière Hospital, Paris France.
Culture of explants from adipose tissue
Explants of epididymal adipose tissue were prepared from ob/ob male mice, following overnight fasting. Epididymal adipose tissue samples were cut into small pieces (1 mm3) under sterile conditions and rinsed in Dulbecco's modified Eagle medium (DMEM, Invitrogen). Explants (200 mg) were further incubated for 48 hours at 37°C in DMEM supplemented with 12.5 mM glucose, 200 IU/ml penicillin, 50 mg/l streptomycin, and 2% BSA, and further exposed to 1 µM JWH-133 (Tocris, France) or vehicle (DMSO 0.02%). After 48 hours, samples were frozen in liquid nitrogen and stored at −80°C before RNA extraction.
Serum analysis
Blood was collected at the time of sacrifice, fasting glycemia were determined by Accu-Check active bands (Roche Diagnostics) and insulinemia by Elisa (Ultrasensitive mouse sensitive Elisa, Mercodia), respectively.
Hepatic triglyceride quantification
Hepatic triglycerides were extracted from 50 mg of liver homogenates by homogenization in 1 ml of chloroform-methanol (21 v/v) using TissueLyser (Qiagen). The homogenate was centrifuged for 10 min at 1000 g, and the lipid phase was diluted with 0.2 ml water. Following an additional centrifugation for 20 min at 2400 rpm, the lipid extract was collected from the lower phase, evaporated and dissolved in 1 ml of 2-propanol. Triglycerides were quantified with a triglyceride determination kit (Sigma), on liver samples from 10–15 animals per group.
Insulin tolerance test
Mice (7–10 per group) underwent a 0.75 U/kg i.p. injection of human insulin (Insulin NPH; Lilly), following a 3 h fasting. Blood samples were taken from the tail vein for determination of glycemia at time 0 and 20, 30, 40, 60, 90, 120, and 180 min after the insulin injection.
Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic- euglycemic clamp was performed as previously described [22]. Briefly, 6h-fasted WT (n=6) and Cnr2 −/− (n=7) mice fed a HFD for 15 weeks, received simultaneous infusions of insulin (18 mU.kg−1.min−1 for 3 h), and D-(3H)3-glucose (30 µCi.kg−1.min−1), Perkin Elmer, Boston, MA) to ensure a detectable D-(3H)3-glucose enrichment. Glycemia was assessed throughout the infusion from blood samples collected from the tip of the tail vein and euglycemia was maintained by adjusting a variable infusion of 30% (wt/vol) glucose. Plasma glucose concentrations and D-(3H)3-glucose specific activity were determined in 5 µl of blood sampled from the tip of the tail vein every 10 min during the last hour of the infusion. The enrichment in D-(3H)3-glucose was determined from total blood after deproteinization by a Zn(OH)2 precipitation as previously described [22]. An aliquot of the protein-free supernatant was evaporated to dryness and mixed with scintillation fluid to determine the radioactivity corresponding to D-[3H]3-glucose. In a second aliquot of the same supernatant, glucose concentration was measured by the glucose oxidase method (Sigma).
RNA preparation and RT-PCR
Total RNA was extracted from mice epididymal fat, liver and brain using RNeasy® Lipid Tissue Mini kit (Qiagen). Quantitative RT-PCR was carried out on a Light Cycler (Roche Diagnostics), as previously described [23]. Oligonucleotide primer sequences of the mouse genes studied were the following. mouse Rn18S: sense 5′-ACCAGAGCGAAAGCATTTGCCA-3′, antisense: 5′-ATCGCCAGTCGGCATCGTTTAT-3′; mouse Cnr2: sense 5′-GGATACAGAATAGCCAGGAC-3′, antisense 5′-GGAGCCGTTGGTCACTTCTG-3′; mouse Cnr1: sense 5′-GGGCAAATTTCCTTGTAGCA-3′, antisense 5′-CTGCAAGGCCGTCTAAGATCGACT-3′; mouse Ccl2: sense 5′-GGGCCTGCTGTTCACAGTT-3′, antisense 5′-CCAGCCTACTCATTGGGAT-3′; mouse Emr1: sense 5′-CTTTGGCTATGGGCTTCCAGTC-3′, antisense 5′-GCAAGGAGGACAGAGTTTATCGTG-3′; mouse Tnf: sense 5′-AATGGCCTCCCTCTCATCAGTT-3′, antisense 5′-CCACTTGGTGGTTTGCTACGA-3′. PCR amplified products were analyzed on a 2% agarose gel and sequenced.
Immunohistochemistry
Immunohistochemical detection of F4/80 was performed in epididymal adipose formalin-fixed, parraffin-embedded tissue sections (8 µm), using non-diluted antibody to F4/80 (Serotec MCA 497) and biotinylated secondary antibody (1/50, Serotec AAR10B). The signal was amplified with phosphatase alkaline–conjugated streptavidin (1/20, Serotec), and alkaline phosphatase activity was revealed using fast red substrate–chromogen system (Dakocytomation). The total number of F4/80 expressing cells was quantified on at least 500 cells from 5 random fields in 7 vehicle-treated or 7 AM-630-treated WT mice fed a HFD, and 5 Cnr2 −/− HFD-fed animals, using Image J software. Results are expressed as F4/80 stained cells/total cells.
Statistics
Results are expressed as mean±SEM and were analyzed by either Mann and Whitney test, one or two way ANOVA as appropriate, using PRISM 4.0 software. P<0.05 was taken as the minimum level of significance.
Results
Characterization of CB2 receptor expression in the adipose tissue and the liver during obesity
We first characterized the expression of Cnr2 (encoding CB2) in the adipose tissue and in the liver, and its regulation overtime during obesity, using genetically obese leptin-deficient ob/ob mice and wild type (WT) C57Bl/6J mice fed a high fat diet (HFD) for 6 or 15 weeks. In the two models, Cnr2 expression was detected in the epididymal adipose tissue of lean animals, and its expression was enhanced in obese mice in parallel to body weight increase (Fig 1A). Moreover, in both models, the induction of fat Cnr2 expression was correlated with adipose tissue inflammation, as shown by the concurrent increase in the expression of Emr1, encoding the macrophage related marker F4/80 (Fig 1A). In keeping, epididymal adipose tissue fractionation experiments showed that Cnr2 was predominantly expressed in the stromal vascular fraction, both in lean ob+/ob and obese ob/ob animals, and was barely detectable in the adipocyte fraction (Fig 1B). Obesity was associated with a modest 1.8-fold increase in Cnr2 expression in the liver, both in ob/ob and HFD-fed animals (Fig 1C). In keeping with findings in the adipose tissue, Cnr2 was primarily expressed by the non parenchymal liver cell fraction in lean ob+/ob and in obese ob/ob animals, whereas Cnr2 was hardly detectable in the hepatocyte fraction (Fig 1D). Overall, these results indicate that obesity enhances Cnr2 expression in the non parenchymal cell fraction of adipose tissue and liver.
Figure 1
Selective distribution of Cnr2 in the adipose tissue and regulation during obesity.
CB2 receptors promote obesity-associated inflammation
Given the regulatory role of Cnr2 in inflammation [15], we next explored the possibility that CB2 receptors may regulate fat and liver inflammation. To that aim, C57Bl/6J mice were fed a HFD or a normal diet (ND) and sacrificed after 6 weeks, i.e at the early onset of inflammation in obese mice. In addition, both groups of mice received a daily intraperitoneal injection of the selective CB2 receptor agonist JWH-133 (3 mg/kg) or its vehicle during the last 2 weeks [24], [25]. Administration of JWH-133 did not affect body weight progression of either HFD or ND-fed mice (Fig 2A). As expected, vehicle-treated HFD-fed mice showed a moderate induction of epididymal fat Emr1 and Tnf expressions, whereas the expression of Ccl2, encoding MCP-1, was already strongly increased (Fig 2B). Interestingly, administration of JWH-133 to ND-fed WT mice induced Emr1 and Tnf expression, as compared to vehicle-treated ND counterparts (Fig 2B). Moreover, the compound further potentiated inductions of fat Emr1 and Tnf in HFD-fed animals (Fig 2B). However, JWH-133 treatment had no effect on Ccl2 expression either in ND or in HFD-fed mice (Fig 2B). The impact of JWH-133 was also investigated in cultured fat pads isolated from ob/ob mice. Cultured fat pads exposed to JWH-133 showed a marked induction in both Tnf and Ccl2 expressions (Fig 2C). Finally, in the liver of mice fed a ND or a HFD, JWH-133 had little or no effect on Ccl2 and Tnf expression respectively (Fig 2D). Taken together, these data demonstrate that the role of CB2 receptor is critical in adipose tissue inflammation, but less determinant in liver inflammation.
Figure 2
Activation of CB2 receptors by JWH-133 enhances fat inflammation in HFD-fed mice.
We next investigated whether CB2 receptor antagonism reduced obesity-associated inflammation. A 2-week treatment of ob/ob mice with the CB2 receptor antagonist AM-630 (1 mg/kg/day) did not affect body weight progression [26] (Fig 3A) while reducing adipose tissue inflammation, as reflected by the reduction in the accumulation of F4/80 positive cells and of Emr1, Tnf and Ccl2 expression (Fig 3B and C). Moreover, in control lean ob+/ob mice there was a trend towards reduced fat inflammation in AM-630 treated animals compared to lean vehicle-exposed controls (Fig 3B and C). These results were confirmed in Cnr2−/− mice fed a HFD for 15 weeks. Compared to HFD-fed WT mice, HFD-fed Cnr2−/− animals exhibited a significant reduction in fat macrophage density (Fig 4A) and a lesser induction of Emr1, Tnf and Ccl2 (Fig 4B). Finally, livers of HFD-fed Cnr2−/− mice also showed a decline in inflammation, as compared to their WT counterparts (Fig 4C). Overall, these data demonstrate that CB2 receptor inactivation reduces inflammation both in adipose tissue and in the liver of obese animals.
Figure 3
Pharmacological inactivation of CB2 receptors reduces the inflammatory response in the adipose tissue.
Figure 4
Cnr2 knock-out reduces the inflammatory response in the adipose tissue and the liver.
Deletion of Cnr2 reduces body weight progression under HFD
Surprisingly, Cnr2 knock-out was also associated with a slower body weight progression that becomes significant after 8 weeks of HFD (p<0.05 by two way ANOVA) (Fig 4D). Accordingly, Cnr2 −/− mice also displayed smaller adiposity index and adipocyte size compared to WT animals (Table 1), and reduced circulating leptin levels, whereas serum adiponectin levels were unchanged (Table 1). Subsequent experiments investigated mechanisms underlying Cnr2 impact on obesity.
Table 1
Metabolic parameters of HFD WT and Cnr2 −/− mice.
Since the cannabinoid receptor CB1 plays a key role in the pathogenesis of obesity by increasing food intake and reducing energy expenditure, we first characterized Cnr1 expression in brain, adipose tissue and liver. There was no difference in brain Cnr1 expression between HFD-fed WT and Cnr2−/− mice. However, surprisingly, Cnr1 expression was decreased in the adipose tissue and the liver of HFD-fed Cnr2 −/− mice as compared to their WT counterparts (Table 1). In contrast, livers and adipose tissue isolated from JWH-133 or AM-630 treated animals showed no difference in Cnr1 levels (not shown). These data suggested that the reduction of Cnr1 expression in the adipose tissue and liver observed in Cnr2 −/− mice might account for the reduction in body weight progression in these animals, a reduction that is not observed in WT mice treated with pharmacological agonists or antagonists of CB2 receptors. The next series of experiments were therefore designed to further delineate the mechanisms underlying the Cnr2−/− mice phenotype.
Several studies have reported that Cnr1 knock-out decreases food intake and increases energy expenditure. However, food intake was similar in Cnr2−/− and WT mice fed a HFD (Table 1). Indirect calorimetry showed that HFD-fed Cnr2 −/− and WT mice had similar basal and total metabolic rate, exhibited the same level of spontaneous activity (Table 1), and equivalent thermogenic response to feeding (not shown). Nevertheless, Cnr2−/− mice tended to display a lower pre-meal, post meal and overall respiratory quotient, although the differences with WT animals did not reach statistical significance (data not shown). In addition, the peak of meal-induced RQ increase was significantly reduced in Cnr2 −/− animals, compared to WT (Table 1), therefore indicating that Cnr2 knock-out may reduce the inhibition of lipid oxidation induced by feeding. Finally, quantification of fat elimination in faeces showed a modest albeit significant increase in fecal lipid output in HFD-fed Cnr2 −/− mice, as compared to WT counterparts (Table 1), by a mechanism that may involve inhibition of pancreatic lipase gene expression (Cadoudal et al, preliminary results). Overall, these data indicate Cnr2 knock-out attenuates the progression of obesity by a mechanism distinct from that elicited by CB1 antagonism, possibly by increasing both lipid oxidation and fecal fat excretion.
CB2 receptors promote insulin resistance
We next examined the impact of CB2 receptors on obesity-associated insulin resistance, a reported consequence of inflammation. As expected, WT mice fed a HFD for 15 weeks developed hyperglycemia and hyperinsulinemia, resulting in increased HOMA-IR (Fig 5A). In contrast, the increase in insulin plasma levels and HOMA-IR was significantly lower in HFD-fed Cnr2 −/− mice (Fig 5A). Consistent with these results, insulin tolerance test showed that HFD-fed Cnr2 −/− mice were more insulin sensitive than their WT counterparts (p<0.05 by two way ANOVA) (Fig 5B). These findings were further corroborated in hyperinsulinemic-euglycemic clamp experiments (Fig 5C). Indeed, glucose turnover and glycolysis rate were increased in HFD-fed Cnr2 −/− mice, whereas glycogen synthesis rate remained unchanged, confirming the insulin sensitizing effects of Cnr2 knock-out (Fig 5C). Accordingly, in mice exposed to a HFD for 6 weeks, treatment with the CB2 agonist JWH-133 enhanced insulin resistance, as assessed by the insulin tolerance test (p<0.05 by two way ANOVA) (Fig 5 D). Collectively, these results demonstrate that CB2 receptors enhance obesity-associated insulin resistance.
Figure 5
CB2 receptors potentiate insulin resistance in HFD-fed mice.
CB2 receptors promote fatty liver
Obesity-associated fatty liver has been causally linked to adipose tissue inflammation and insulin resistance. As expected, WT mice fed a HFD for 15 weeks developed severe fatty liver (Fig 6A). In contrast, HFD-fed Cnr2 −/− animals exhibited minimal steatosis, as illustrated by the decrease in the steatosis score (Fig 6A) and the decline in liver triglyceride concentration, compared to HFD-fed WT animals (Fig 6B). In keeping with these results, administration of JWH-133 enhanced liver triglyceride accumulation in WT mice fed a HFD for 6 weeks (Fig 6B). Taken together, these findings indicate that CB2 receptors potentiate obesity-associated fatty liver.
Figure 6
CB2 receptors promote the development of hepatic steatosis.
Discussion
Our study unravels a previously unrecognized contribution of CB2 receptors to the pathogenesis of obesity associated-comorbodities via an impact on obesity-associated inflammation, insulin resistance and fatty liver.
Recent studies have conclusively shown that adipose tissue and liver inflammation plays a major role in obesity-associated insulin resistance and NAFLD [4]–[7], [27], [28]. Our data indicate that during obesity progression, Cnr2 expression undergoes a strong increase in adipose tissue parallel to the development of fat inflammation, and a moderate induction in the liver. Tissue fractionation experiments show that enhancement of Cnr2 expression arises from the macrophage-enriched stromal vascular fraction of the adipose tissue and the non parenchymal liver cell fraction, whereas Cnr2 expression in adipocytes and hepatocytes remains negligible. Pharmacological activation of CB2 receptors has no significant impact on liver inflammation but promotes a significant enhancement of adipose tissue inflammation at an early stage. Indeed, administration of JWH-133 at the onset of inflammation, i.e. in mice fed a HFD for 6 weeks, increases fat macrophage infiltration and the related inflammatory response. Moreover, pharmacological and genetic CB2 receptor inactivation reduce adipose tissue and liver inflammation in the long term, as shown in ob/ob mice or animals fed a HFD for 15 weeks. Interestingly, in isolated fat pads, the CB2 receptor agonist JWH-133 upregulates Ccl2 and Tnf, demonstrating the direct impact of CB2 receptors to adipose tissue inflammation. Nevertheless, in light of previous data showing Cnr2 expression in human adipocytes and in adipocyte cell lines [29], [30], the contribution of adipocyte CB2 receptors to fat inflammation cannot be definitively ruled out. Mechanisms underlying the impact of CB2 receptors on macrophage recruitment remain to be determined. Potential pathways could involve enhanced chemotaxis and/or increased macrophage migration, considering reported stimulatory effects of CB2 receptors on these two functions in other conditions [15], [31]–[33]. The relative contribution of liver vs adipose tissue inflammation remains to be determined. Nevertheless, our data unravel the critical role of CB2 receptors in obesity-associated inflammation.
Insulin resistance associated with obesity has been linked to adipose tissue inflammation [4]–[7]. In keeping with these studies, our data suggest that proinflammatory properties of adipose tissue CB2 receptors may contribute to the development of insulin resistance. Indeed, under HFD, JWH-133-treated WT mice show enhanced insulin resistance and fat inflammation, whereas Cnr2 −/− mice display improved insulin sensitivity and reduced fat inflammation. It should also be stressed that, aside from their impact on fat inflammation, CB2 receptors expressed by other insulin sensitive tissues, including skeletal muscle and liver [23], [34], [35] may also contribute to insulin resistance. In addition, deleterious effects of CB2 receptors on insulin secretion may also be expected, in light of the inhibition of insulin secretion triggered by CB2 receptors expressed in pancreatic β cells [35], [36].
Our results indicate that fatty liver, a hallmark of obesity-associated metabolic syndrome, is enhanced by the CB2 receptor agonist JWH-133 and blunted by Cnr2 knock-out. Recent data have conclusively shown a causal relationship between obesity-induced overproduction of fat inflammatory mediators such as Ccl2, insulin resistance and steatogenesis. Indeed, insulin resistance enhances the release of non-esterified fatty acids from adipose tissue, leading to increased fatty acid storage in hepatocytes [10]. Moreover, mice overexpressing Ccl2 specifically in adipose tissue exhibit insulin resistance and increased hepatic triglyceride content. Conversely, knock-out of Ccl2 or its receptor Ccr2, improves insulin sensitivity and prevents steatosis [27], [28], [37]. Therefore, it is tempting to speculate that CB2 receptors may enhance fatty liver at least partly by increasing adipose tissue inflammation and the related induction of Ccl2. Other steatogenic mechanisms may include enhancement of lipogenesis and/or inhibition of fatty acid β-oxidation in hepatocytes, following direct activation of Cnr2. However, although expressed in the liver [23], CB2 receptors are undetectable in steatotic hepatocytes.
Recent studies in obese patients have reported elevated circulating levels of the endogenous CB2 ligand 2-arachidonoylglycerol [38] and increased production of the compound by fat cells [39]. These observations, together with our findings demonstrating induction of CB2 receptor in adipose tissue and liver, indicate that alike CB1 tone, the endogenous CB2 tone is increased during obesity [40], [41]. Clinical and experimental studies in obesity have also linked overactivation of CB1 receptors to body weight progression, insulin resistance and fatty liver [11], [14], [42]–[45]. Interestingly, although both receptors display convergent effects, pathways underlying CB1 effects are markedly different from those affected by CB2. Indeed, CB1 receptors mainly enhance food intake, reduce peripheral energy expenditure and enhance hepatic lipogenesis via CB1 receptors expressed by hepatocytes. In contrast, pharmacological modulation of CB2 receptors has no impact on either food intake or body weight progression and predominantly affects adipose tissue inflammation. It should however be pointed out that Cnr2 knock-out was associated with a slight reduction of body weight progression under HFD, that was not observed in WT animals exposed to CB2 agonists or antagonists. This discrepancy may result from developmental defects linked to lifelong absence of CB2 receptors or may be due to the short duration of treatment with the CB2 targeting molecules in our experiments. Nevertheless, our findings indicate that distinct CB1 and CB2 receptor-dependent pathways significantly contribute to the pathogenesis of insulin resistance and NAFLD.
In conclusion, the present study uncovers the potent proinflammatory properties of CB2 receptors during experimental obesity and shows the deleterious impact of CB2 receptors on insulin resistance and fatty liver. These findings further document the crucial role of the endocannabinoid system in metabolic comorbidities associated to obesity, and unravel the previously unrecognized role of CB2 receptors. They also demonstrate that both CB1 and CB2 receptors display convergent effects, via complementary pathways [11], [13], [14]. Finally, our results add novel evidences underscoring the role of CB2 receptors in the pathogenesis of inflammatory disorders [15] and liver diseases [12], [17], [23], [45]–[48]. Lastly, our results suggest that CB2 receptor antagonism may open a novel therapeutic approach for the management of insulin resistance and fatty liver.
Acknowledgments
We thank F. Pecker for helpful and constant guidance, C. Pavoine for helpful comments and S. Balustre for animal handling.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the INSERM, the Universite Paris-Val-de-Marne, and by grants (to SL) of the Agence Nationale de la Recherche and the Fondation pour la Recherche Medicale. V Deveaux was supported by a fellowship from the Association Francaise pour l′Etude du Foie, Y Ichigotani by a fellowship from the Agence Nationale de la Recherche and T Cadoudal by a fellowship from the Fondation pour la Recherche Medicale. A Bertola was successively supported by the Programme Hospitalier de Recherche Clinique (CHU of Nice) and the Association pour la Recherche sur le Cancer. Y Le-Marchand Brustel and P Gual are the recipients of an interface grant from CHU of Nice, and S Lotersztajn of an interface grant from AP-HP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887. [PubMed]
2. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209. [PubMed]
3. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191–2207. [PubMed]
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808. [PMC free article] [PubMed]
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. [PubMed]
6. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180. [PubMed]
7. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830. [PMC free article] [PubMed]
8. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117:2877–2888. [PMC free article] [PubMed]
9. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes. 2009;58:125–133. [PMC free article] [PubMed]
10. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829–838. [PMC free article] [PubMed]
11. Di Marzo V. Targeting the endocannabinoid system:to enhance or reduce? Nature Reviews Drug Discovery. 2008;7:438–455.
12. Mallat A, Lotersztajn S. Endocannabinoids and Their Receptors in the Liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9–G12. [PubMed]
13. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462. [PMC free article] [PubMed]
14. Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1101–1104. [PubMed]
15. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–411. [PubMed]
16. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature Medicine. 2005;434:782–786.
17. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, et al. CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol. 2008;153:286–289. [PMC free article] [PubMed]
18. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. Faseb J. 2007;21:1788–1800. [PMC free article] [PubMed]
19. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141–149. [PubMed]
20. Even PC, Perrier E, Aucouturier JL, Nicolaidis S. Utilisation of the method of Kalman filtering for performing the on-line computation of background metabolism in the free-moving, free-feeding rat. Physiol Behav. 1991;49:177–187. [PubMed]
21. Even PC, Mokhtarian A, Pele A. Practical aspects of indirect calorimetry in laboratory animals. Neurosci Biobehav Rev. 1994;18:435–447. [PubMed]
22. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005;115:3554–3563. [PMC free article] [PubMed]
23. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–755. [PubMed]
24. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, et al. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem. 1999;7:2905–2914. [PubMed]
25. Defer N, Wan J, Souktani R, Escoubet B, Perier M, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. Faseb J 2009
26. Pertwee R, Griffin G, Fernando S, Li X, Hill A, et al. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 1995;56:1949–1955. [PubMed]
27. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602–26614. [PubMed]
28. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–1505. [PMC free article] [PubMed]
29. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 2006;126:177–187. [PubMed]
30. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171–3180. [PubMed]
31. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol. 2008;153:299–308. [PMC free article] [PubMed]
32. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol. 2008;294:H1145–1155. [PubMed]
33. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, et al. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem. 2000;275:15621–15628. [PubMed]
34. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol. 2007;267:63–69. [PubMed]
35. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553–565. [PubMed]
36. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 2006;39:155–162. [PubMed]
37. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115–124. [PMC free article] [PubMed]
38. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843. [PMC free article] [PubMed]
39. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007;15:837–845. [PubMed]
40. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–3060. [PMC free article] [PubMed]
41. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692–699. [PubMed]
42. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007;46:122–129. [PubMed]
43. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. Paracrine Activation of Hepatic CB(1) Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver. Cell Metab. 2008;7:227–235. [PubMed]
44. Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 2006;6:586–591. [PubMed]
45. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology. 2005;42:63–71.
46. Teixeira-Clerc F, Julien B, Grenard P, Tran-Van-Nhieu J, Deveaux V, et al. CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676.
47. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, et al. Daily cannabis use, a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432–439.
48. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. Journal of Endocrinological Investigation. 2006;29:58–65. [PubMed]
Source: Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
